Treatment targeting co-inhibitory immune checkpoint molecules including PD-1, CTLA-4, and LAG-3 have become the cornerstones of management for melanoma, and other solid tumors.13 Combined checkpoint blockade has been the most effective therapeutic strategy for advanced melanoma for nearly a decade, and has recently entered the neoadjuvant setting. This evidence concerns the gene CTLA4 and melanoma.